Covestor
VKTX icon

Covestor’s Viking Therapeutics VKTX Stock Holding History

Covestor’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8K Sell
245
-8
-3% -$277 0.01% 1685
2026
Q2 		$10K Buy
253
+17
+7% +$549 0.01% 1630
2026
Q1 		$8K Sell
236
-188
-44% -$6.04K 0.01% 1623
2025
Q4 		$15K Hold
424
– – 0.01% 1412
2025
Q3 		$11K Sell
424
-1
-0.2% -$30 0.01% 1575
2025
Q2 		$11K Sell
425
-829
-66% -$21.8K 0.01% 1567
2025
Q1 		$30K Buy
1,254
+1,094
+684% +$34.6K 0.02% 1048
2024
Q4 		$6K Buy
160
+2
+1% +$114 ﹤0.01% 1703
2024
Q3 		$10K Buy
158
+1
+0.6% +$59 0.01% 1590
2024
Q2 		$8K Buy
157
+153
+3,825% +$10K 0.01% 1695
2024
Q1 		$0 Sell
4
-4
-50% -$178 ﹤0.01% 2790
2023
Q4 		$0 Sell
8
-1
-11% -$13 ﹤0.01% 2766
2023
Q3 		$0 Buy
+9
New +$129 ﹤0.01% 2761

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Covestor's VKTX Position: Q3 2026 in Review

Covestor reduced its Viking Therapeutics (VKTX) stake by 3.2% in Q3 2026, selling an estimated $277 and leaving 245 shares worth $8K. The position accounts for 0.01% of the portfolio, ranked #1685.

Covestor first reported a position in VKTX in Q3 2023 and has held it in 13 quarters since. The position peaked at $30K in Q1 2025. 322 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Covestor held 245 shares of Viking Therapeutics worth $8K as of Q3 2026.
  • Covestor sold 8 Viking Therapeutics shares in Q3 2026, an estimated $277.
  • Viking Therapeutics made up 0.01% of Covestor's portfolio in Q3 2026, its #1685 holding.
  • Covestor first reported a position in Viking Therapeutics in Q3 2023 and has held it in 13 quarters since.
  • Covestor's Viking Therapeutics position peaked at $30K in Q1 2025.
  • 322 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.